Abstract：Objective: To evaluate the predictive value of serum S100B expression in brain metastasis risk for patients with small cell lung cancer (SCLC) and its association with clinicopathological characteristics of SCLC patients. Methods: 20 SCLC patients with brain metastases, 24 SCLC patients without brain metastases and 16 post-operative SCLC patients as control group were enrolled in this case-control study. The serum levels of S100B in three groups were detected by ELISA. Results: Serum S100B levels in SCLC patients with brain metastases were markedly increased compared with SCLC patients without brain metastasis and postoperative SCLC patients (all P<0.001). Receiver Operating Characteristic (ROC) showed that serum S100B level had a good predictive value for brain metastasis in SCLC patients(SCLC patients with brain metastases vs. SCLC patients without brain metastases: AUC 0.840 (95% CI: 0.721~0.958); SCLC patients with brain metastases vs. post-operative SCLC patients: AUC 0.906 (95% CI: 0.811~1.000)). Multivariate regression analysis displayed that high level of serum S100B was an independent factor in predicting brain metastasis risk in SCLC patients (P=0.025). In addition, serum S100B level was positive associated with N stage in SCLC patients with brain metastases (P=0.019). Spearman rank correlation analysis revealed that serum S100B level was positively correlated with Neuron Specific Enolase (NSE) in SCLC patients with brain metastases (r=0.508, P=0.022). Conclusion: Serum S100B could be a promising biomarker of brain metastasis risk in SCLC patients, and it is positively correlated with N stage and NSE level in SCLC patients with brain metastasis.
颜波, 毛晓伟, 张伟, 储天晴, 钟华, 姜丽岩. 血清S100B蛋白表达水平对小细胞肺癌患者脑转移风险的预测价值[J]. 河北医学, 2018, 24(4): 591-596.
YAN Bo, MAO Xiaowei, ZHANG Wei, et al. The Predictive Value of the Level of Serum S100B Protein Expression on the Risk of Brain Metastasis in Patients with Small Cell Lung Cancer. HeBei Med, 2018, 24(4): 591-596.
[1] Van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer[J]. Lancet, 2011, 378(9804): 1741~1755. [2] Baize N, Monnet I, Greillier L, et al. Second-line treatments of small-cell lung cancers[J]. Expert Rev Anticancer Ther, 2017, 17(11): 1033~1043. [3] Lee SH. Role of chemotherapy on brain metastasis[J]. Prog Neurol Surg, 2012, 25: 110~114. [4] Choi H, Puvenna V, Brennan C, et al. S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer[J]. Transl Lung Cancer Res, 2016, 5(4): 413~419. [5] Wu L, Zhou X, Xiao Z, et al. Functional expression, characterization, and application of human S100B[J]. Oncol Rep, 2017, 38(4): 2309~2316. [6] Kuwar RB, Stokic DS, Leis AA, et al. Does astroglial protein S100B contribute to West Nile neuro-invasive syndrome[J].Neurol Sci, 2015, 358(1-2): 243~252. [7] Weide B, Richter S, Buttner P, et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy[J]. PLoS One, 2013, 8(11): e81624. [8] Vogelbaum MA, Masaryk T, Mazzone P, et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage[J]. Cancer, 2005, 104(4): 817~824. [9] Egberts F, Pollex A, Egberts JH, et al. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH[J]. Onkologie, 2008, 31(7): 380~384. [10] Gu XH, Zhang G, Zhang XQ, et al. Clinical values of detection of serum levels of S100B and NSE in diagnosis of brain injuries at early period after cardiopulmonary bypass[J]. Zhonghua Yi Xue Za Zhi, 2007, 87(14): 975~977. [11] Darlix A, Lamy PJ, Lopez-crapez E, et al. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases[J]. Int Cancer, 2016, 139(10): 2299~2311.
2018, Vol. 24 
冀公网安备13080202000677号